ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.

C. Legendre,1 J. Campistol,2 T. Feldkamp,3 J. Wang,4 G. Remuzzi,5 L. Weekers,6 N. Sheerin.7

1Université
Paris Descartes & Hôpital Necker, Paris, France
2Hospital Clinic, University of Barcelona, Barcelona, Spain
3University Hospital Schleswig-Holstein, Kiel, Germany
4Alexion Pharmaceuticals, Inc., Cheshire, CT
5IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
6CHU de Liège, Liège, Belgium
7Newcastle University, Newcastle upon Tyne, United Kingdom.

Meeting: 2016 American Transplant Congress

Abstract number: 402

Keywords: Glomerular filtration rate (GFR), Hemolytic-uremic syndrome, Kidney transplantation, Renal failure

Session Information

Date: Tuesday, June 14, 2016

Session Name: Concurrent Session: It's Just Not the Donor: Impact of Recipient Factors on Outcomes

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:18pm-3:30pm

Location: Ballroom A

Related Abstracts
  • 1-Year Safety and Efficacy of Eculizumab in Adult aHUS Patients, With or Without a History of Renal Transplant
  • Eculizumab in aHUS Pts with Long Disease Duration, with or without Renal Transplant

Purpose: aHUS often progresses to ESRD and requires transplant (tx). Eculiumab (ECU), a terminal complement inhibitor, inhibits TMA irrespective of tx status. We evaluated outcomes in patients (pts) with aHUS and native and tx kidneys treated with ECU.

Methods: Efficacy and safety data over 18 months from 4 phase 2 trials of ECU with long-term extensions were analyzed post hoc.

Results: Data from 100 pts (74 with native kidneys; 26 with 38 tx prebaseline) were pooled. At baseline, extent of renal injury (ie, age, time from diagnosis to treatment, and TMA history) differed (P≤0.0002; Table). No grafts were lost on ECU. One pt in ESRD for >4 months prebaseline was txed after ECU initiation. Median (range) ECU duration was 71 (0–186) weeks. Median (range) eGFR increased from baseline to 18 months to 60 (9-130) and 38 (6-107) mL/min/1.73 m2 for pts with native and tx kidneys (Table). ECU was well tolerated; most adverse events were mild or moderate. Meningococcal infections occurred in 2 pts (1 native kidney, serogroup B; 1 with tx, serogroup unknown). Both were vaccinated; neither received prophylactic antibiotics at time of infection. Infections resolved with antibiotics; the pt with the native kidney continued ECU.

Conclusion: Graft loss occurs at a high rate in txed pts with aHUS prior to ECU. ECU was well tolerated and improved renal function in pts with aHUS with native and txed kidneys. No pts with prebaseline tx lost grafts during ECU treatment. Extent of previous renal injury influences changes in eGFR in pts with aHUS (Nephrol Dial Transplant. 2015;30[suppl 3]:SaO008), particularly those with tx (Am J Transplant. 2012;12:3337–54). These data suggest that early recognition and treatment of aHUS optimizes renal outcomes.

CITATION INFORMATION: Legendre C, Campistol J, Feldkamp T, Wang J, Remuzzi G, Weekers L, Sheerin N. Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Legendre C, Campistol J, Feldkamp T, Wang J, Remuzzi G, Weekers L, Sheerin N. Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-outcome-with-eculizumab-in-patients-with-ahus-with-native-and-transplanted-kidneys-pooled-analysis-of-100-patients/. Accessed February 27, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.